ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, the first tyrosine kinase inhibitor developed and approved by the US Food and Drug Administration (FDA) – imatinib – targets the ABL kinase and has revolutionized the treatment of patients with CML [100, 101].